NCT01165684CompletedPhase 4
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 401
- Locations
- 1
- Primary Endpoint
- Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 32
Study Overview
Brief Summary
This trial is conducted in Europe, and North and South America. The aim of this clinical trial is to investigate if the two treatments are equally effective.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Type 2 diabetes (diagnosed clinically) for at least 12 months
- •Basal insulin treatment (NPH once or twice daily, insulin glargine once daily or insulin detemir once daily) for at least 6 months
- •HbA1c: 7.0-9.0 % (both inclusive) by central laboratory analysis (one retest analysed at the central laboratory within a week is permitted with the result of the last sample being conclusive)
- •BMI (Body Mass Index) less than 40.0 kg/m^2
Exclusion Criteria
- •Previous use of pre-mix or bolus insulin (allowed is previous use of bolus insulin only in case of a hospitalisation or a severe condition requiring intermittent use of bolus insulin for less than 14 consecutive days, but not during the last 6 months prior to screening visit (Visit 1)
- •Use of GLP-1 (Glucagon-like peptide-1) receptor agonists or pramlintide within the last 6 months prior to prior to screening visit (Visit 1)
- •Anticipated change in concomitant medication known to interfere significantly with glucose metabolism (e.g. systemic corticosteroids, beta-blockers, MAO (Monoamine oxidase) inhibitors, etc.)
- •Cardiovascular disease, within the last 12 months prior to screening visit (Visit 1), defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
- •Uncontrolled treated/untreated severe hypertension (systolic blood pressure sitting at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg). For Argentina: systolic blood pressure sitting at least 150 mmHg and/or diastolic blood pressure at least 90 mmHg
- •Impaired liver function, defined as ALAT (Alanine aminotransferase) at least 2.5 times upper limit of normal (one retest analysed at the central laboratory within a week is permitted with the result of the last sample being conclusive)
- •Impaired renal function defined as serum creatinine above 135 micromol/L (above 1.5 mg/dL) for males and above 110 micromol/L (above 1.2 mg/dL) for females; and, if required by the locally applicable metformin label, glomerular filtration rate below 60 ml/min, calculated by the Cockroft & Gault formula). One retest within a week is permitted with the result of the last sample being conclusive
- •Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic episode, during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months
- •Proliferative retinopathy or maculopathy requiring treatment according to the Investigator
- •Treatment with OADs (Oral anti-diabetic drug) contraindicated or unapproved for combination treatment with insulin (according to local OAD label)
Arms & Interventions
Step-wise
Experimental
Intervention: insulin aspart (Drug)
Step-wise
Experimental
Intervention: insulin detemir (Drug)
Basal-bolus
Active Comparator
Intervention: insulin aspart (Drug)
Basal-bolus
Active Comparator
Intervention: insulin detemir (Drug)
Outcomes
Primary Outcomes
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 32
Time Frame: Week 0, Week 32
Estimated mean change from baseline in HbA1c after 32 Weeks of treatment
Secondary Outcomes
- Fasting Plasma Glucose (FPG) at Week 21(Week 21)
- Body Mass Index (BMI) at Week 32(Week 32)
- Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 10(Week 0, Week 10)
- Mean Plasma Glucose Increment Over 3 Meals (Breakfast, Lunch and Dinner) at Week 32(Week 32)
- Body Weight at Week 32(Week 32)
- Proportion of Subjects Reaching Glycosylated Haemoglobin (HbA1c) Below 7.0% at Week 10(Week 10)
- Proportion of Subjects Reaching Glycosylated Haemoglobin (HbA1c) Below 7.0% at Week 21(Week 21)
- Fasting Plasma Glucose (FPG) at Week 10(Week 10)
- Mean Plasma Glucose Increment Over 3 Meals (Breakfast, Lunch and Dinner) at Week 10(Week 10)
- Mean Plasma Glucose Increment Over 3 Meals (Breakfast, Lunch and Dinner) at Week 21(Week 21)
- Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 21(Week 0, Week 21)
- Hypoglycaemic Episodes (Rate of All Treatment Emergent Hypoglycaemia Episodes)(Week 0 to Week 32)
- Proportion of Subjects Reaching Glycosylated Haemoglobin (HbA1c) Below 7.0% at Week 32(Week 32)
- Fasting Plasma Glucose (FPG) at Week 32(Week 32)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01232491Novo Nordisk A/S611
Completed
Phase 3
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia ACongenital Bleeding DisorderHaemophilia ANCT01138501Novo Nordisk A/S65
Completed
Phase 4
Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01467401Novo Nordisk A/S292
Terminated
Phase 2
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MethotrexateInflammationRheumatoid ArthritisNCT01636843Novo Nordisk A/S298
Terminated
Phase 2
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa BiologicsInflammationRheumatoid ArthritisNCT01636817Novo Nordisk A/S239